SGLT2 inhibitors and the changing landscape for treatment of diabetes
Shuangbo Liu,1 Anna Lam,2 Arslan Wazir,1 Asim N Cheema11Terrence Donnelly Heart Centre, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada; 2Division of Endocrinology, University of Alberta, Edmonton, Alberta, CanadaAbstract: Type 2 diabetes mellitus has become an epide...
Saved in:
| Main Authors: | Liu S, Lam A, Wazir A, Cheema AN |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2019
|
| Subjects: | |
| Online Access: | https://doaj.org/article/6d6b83cb2f074f5bbf94386e9a47467a |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
by: Aurélie Pahud de Mortanges, et al.
Published: (2021) -
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
by: Simes BC, et al.
Published: (2019) -
Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
by: Yaohui Jiang, et al.
Published: (2021) -
Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
by: Liu Y, et al.
Published: (2021) -
12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus
by: Perna S, et al.
Published: (2018)